Bone loss and fracture risk associated with thiazolidinedione therapy

Pharmacotherapy

Volumn 30, Issue 7, 2010, Pages 716-727

  Riche, Daniel M ^a,b   King, S Travis ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Bone loss; Diabetes; Fractures; Osteoporosis; Pioglitazone; Rosiglitazone; Thiazolidinedione

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PIOGLITAZONE; PLACEBO; RISEDRONIC ACID; ROSIGLITAZONE; TROGLITAZONE; VITAMIN D; ZOLEDRONIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ABDOMINAL PAIN; ARTHRALGIA; BONE DENSITY; DRUG FEVER; DYSPEPSIA; ESOPHAGUS ULCER; FRACTURE; HEADACHE; HUMAN; JAW OSTEONECROSIS; MYALGIA; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; SIDE EFFECT; BONE; BONE DISEASES, METABOLIC; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; FRACTURES, BONE; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POSTMENOPAUSE; PPAR GAMMA; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; THIAZOLIDINEDIONES;

EID: 77954136691     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.7.716     Document Type: Review

References (41)

1. National Osteoporosis Foundation. Fast facts on osteoporosis. 2005. Available from http://www.nof.org/awareness2/images/Fast-Facts.pdf. Accessed March 20, 2009.
2. Kilgore ML, Morrisey MA, Becker DJ, et al. Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005. J Bone Miner Res 2009;24:2050-5.
3. O'Connel MB, Vondracek SF. Osteoporosis and other metabolic bone diseases. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York: McGraw-Hill, 2008:1483-504.
4. National Institute of Diabetes and Digestive and Kidney Diseases-National Diabetes Information Clearinghouse. National diabetes statistics, 2007. Available from http://diabetes.niddk.nih.gov/DM/PUBS/statistics/. Accessed March 20, 2009.
5. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2.
6. Lamb E. Top 200 prescription drugs of 2008. Available from http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs- 0509. Accessed October 15, 2009.
7. Schwartz AV. TZDs and bone: a review of the recent clinical evidence [online exclusive article]. PPAR Res 2008;2008: 297893. Available from http://www.hindawi.com/ journals/ppar/2008/297893.html.
8. Jackson SM, Demer LL. Peroxisomeproliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000;417:119-24.
9. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, Kim YK. Activation of peroxisomeproliferator-activated receptor-gamma (PPAR-γ) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006;215:198-207.
10. Rzonka SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6.
11. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35.
12. Akune T, Ohba S, Kamekura S, et al. PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-55.
13. Grey A, Bolland M, Gamble G, et al. The peroxisome-proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10.
14. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008;93:1696-701.
15. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-30.
16. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54.
17. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5.
18. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
19. Khan SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from ADOPT. Diabetes Care 2008;31:845-51.
20. Spanheimer R, for Takeda Pharmaceuticals North America, Inc. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus. Letter to healthcare providers, 2007. Available from http:// www.fda.gov/medwaTCH/safety/2007/Actosmar0807.pdf. Accessed March 20, 2009.
21. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009;373:2125-35.
22. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008;75:739-50.
23. Melton LJ, Looker AC, Sheperd JA, et al. Osteoporosis assessement by whole body region vs site-specific DXA. Osteoporos Int 2005;16:1558-64.
24. Schwartz AV. Diabetes, TZDs, and bone: a review of the clinical evidence [online exclusive article]. PPAR Res 2006;2006:24502. Available from http://www.hindawi.com/journals/ppar/2006/024502.abs.html.
25. Beck TJ, Petit MA, Wu G, LeBoff MS, Cauly JA, Chen Z. Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res 2009;8:1369-79.
26. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8.
27. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-54.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-202.
29. Hangartner TN, Johnston CC. Influence of fat on bone measurements with dual-energy absorptiometry. Bone Miner 1990;9:71-81.
30. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis, 2008. Washington, DC: National Osteoporosis Foundation. Available from http://www.nof.org/professionals/NOF-Clinicians- Guide.pdf. Accessed June 2, 2009.
31. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board. Dietary reference intakes: recommended intakes for individuals, vitamins. United States Department of Agriculture national agricultural library. Available from http://iom.edu/en/Global/News Announcements/~/media/Files/ ActivityFiles/Nutrition/DRIs/DRISummaryListing2.ashx. Accessed November 25, 2009.
32. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board. Dietary reference intakes: recommended intakes for individuals, elements. United States Department of Agriculture national agricultural library. Available from http://iom.edu/en/Global/News Announcements/~/media/Files/ ActivityFiles/Nutrition/DRIs/DRISummaryListing2.ashx. Accessed November 25, 2009.
33. Sawada K, Morishige K, Nishio Y, et al. Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal patients. J Bone Miner Metab 2009;27:175-81.
34. Merck & Co., Inc. Fosamax (alendronate) package insert. Whitehouse Station, NJ; 2009.
35. Roche Laboratories, Inc. Boniva (ibandronate) package insert. Nutley, NJ; 2008.
36. Proctor & Gamble Pharmaceuticals, Inc. Actonel (risedronate) package insert. Cincinnati, OH; 2009.
37. Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) package insert. East Hanover, NJ; 2009.
38. Roche Laboratories, Inc. Boniva Injection (ibandronate) package insert. Nutley, NJ; 2009.
39. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate-associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90.
40. Eli Lilly and Company. Forteo (teriparatide) package insert. Indianapolis, IN; 2008.
41. Lui H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teraperatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209-17.